Regeneron Pharmaceuticals (NASDAQ:REGN) has been given a $453.00 price objective by stock analysts at Leerink Swann in a research note issued on Tuesday, Stock Target Advisor reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Leerink Swann’s target price would indicate a potential upside of 47.96% from the stock’s current price.

Several other equities research analysts have also commented on REGN. Guggenheim lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $466.00 to $425.00 in a report on Friday, February 22nd. Piper Jaffray Companies boosted their price target on shares of Regeneron Pharmaceuticals to $487.00 and gave the company an “overweight” rating in a report on Tuesday, February 26th. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Jefferies Financial Group reduced their price target on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a report on Wednesday, April 17th. Finally, Cowen restated a “hold” rating and issued a $353.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 7th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and an average price target of $395.78.

NASDAQ:REGN opened at $306.16 on Tuesday. Regeneron Pharmaceuticals has a one year low of $295.27 and a one year high of $442.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78. The stock has a market capitalization of $33.55 billion, a PE ratio of 15.46, a price-to-earnings-growth ratio of 1.45 and a beta of 1.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing the consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.76 billion. During the same quarter in the prior year, the firm posted $4.67 EPS. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals will post 18.37 earnings per share for the current year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total transaction of $305,930.00. Following the transaction, the director now owns 11,323 shares in the company, valued at approximately $3,464,045.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Neil Stahl sold 9,853 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the transaction, the executive vice president now owns 47,450 shares in the company, valued at approximately $14,507,363. The disclosure for this sale can be found here. Insiders own 11.84% of the company’s stock.

Institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its holdings in Regeneron Pharmaceuticals by 1.9% during the first quarter. BlackRock Inc. now owns 6,042,908 shares of the biopharmaceutical company’s stock worth $2,481,339,000 after buying an additional 113,683 shares in the last quarter. Vanguard Group Inc boosted its holdings in Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after buying an additional 75,868 shares in the last quarter. FMR LLC boosted its holdings in Regeneron Pharmaceuticals by 6.6% during the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after buying an additional 330,875 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in Regeneron Pharmaceuticals by 0.5% during the first quarter. Loomis Sayles & Co. L P now owns 3,176,687 shares of the biopharmaceutical company’s stock worth $1,304,411,000 after buying an additional 15,540 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 1.8% during the first quarter. Geode Capital Management LLC now owns 1,097,848 shares of the biopharmaceutical company’s stock worth $450,007,000 after buying an additional 19,395 shares in the last quarter. Institutional investors and hedge funds own 66.96% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Leveraged Buyout (LBO) Explained

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.